Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

Company Overview

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes.

Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.

Key Stats

• Today's Range: $21.49 to $21.53
• 50-Day Range: $10.03 to $21.53
• 52-Week Range: $5.64 to $21.53
• Volume: 2.99 million shs
• Average Volume: 1.52 million shs
• Market Capitalization: $2.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.29
• Consensus Rating: Hold

Day One Biopharmaceuticals Stock Analysis - MarketRank™

Day One Biopharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 572nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Hold

Consensus Rating

Day One Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 8 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Day One Biopharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Day One Biopharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($0.86) to $0.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Day One Biopharmaceuticals is -20.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Day One Biopharmaceuticals is -20.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Day One Biopharmaceuticals has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.79% of the float of Day One Biopharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 5.39.

Change versus previous month

Short interest in Day One Biopharmaceuticals has recently decreased by 9.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Day One Biopharmaceuticals does not currently pay a dividend.

Dividend Growth

Day One Biopharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Day One Biopharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

MarketBeat Follows

2 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $422,948.00 in company stock.

Percentage Held by Insiders

6.20% of the stock of Day One Biopharmaceuticals is held by insiders.

Percentage Held by Institutions

87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DAWN Stock Analysis - Frequently Asked Questions

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) announced its quarterly earnings data on Tuesday, February, 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.04. The company earned $53.72 million during the quarter, compared to analyst estimates of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative trailing twelve-month return on equity of 23.43%.
Read the conference call transcript.

When did Day One Biopharmaceuticals IPO?

Day One Biopharmaceuticals (DAWN) raised $150 million in an initial public offering on Wednesday, May 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.22%), ABC Arbitrage SA (0.22%), Credit Industriel ET Commercial (0.13%) and SG Americas Securities LLC (0.12%). Insiders that own company stock include Ai Day1 Llc, Samuel C Blackman, Charles N York II, Jeremy Bender, Adam Dubow, Lauren Merendino, Saira Ramasastry and Michael Vasconcelles.
View institutional ownership trends.

What other stocks do shareholders of Day One Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

• Last Earnings: 2/24/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DAWN
• CIK: 1845337
• Web: dayonebio.com
• Phone: 650-484-0899
• Fax: N/A
• Employees: 60
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Day One Biopharmaceuticals: $23.29
• High Price Target: $34.00
• Low Price Target: $17.00
• Potential Upside/Downside: +8.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$107.32 million
• Net Margins: -67.85%
• Pretax Margin: -69.10%
• Return on Equity: -23.43%
• Return on Assets: -20.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.02
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $158.18 million
• Price / Sales: 14.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.30 per share
• Price / Book: 5.01

Miscellaneous

• Outstanding Shares: 103,330,000
• Free Float: 96,927,000
• Market Cap: $2.22 billion
• Optionable: Optionable
• Beta: -1.74